Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b, Prospective, Open-Label, Uncontrolled, Multicenter Study on Long-Term Safety and Efficacy of rVWF in Pediatric and Adult Subjects With Severe Von Willebrand Disease (VWD)

NCT03879135 is registered in ClinicalTrials.gov with Baxalta now part of Shire as lead sponsor.

NCT NCT03879135
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03879135 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b, Prospective, Open-Label, Uncontrolled, Multicenter Study on Long-Term Safety and Efficacy of rVWF in Pediatric and Adult Subjects With Severe Von Willebrand Disease (VWD)
Lead sponsor
Baxalta now part of Shire
Phase
Phase 3
Overall status
Completed
Start date
April 1, 2019
Completion date
January 30, 2025
Enrollment
38 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

von willebrand disease (vwd)